Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.24
CPIX's Cash-to-Debt is ranked higher than
55% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. CPIX: 4.24 )
Ranked among companies with meaningful Cash-to-Debt only.
CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16  Med: 10.92 Max: No Debt
Current: 4.24
1.16
No Debt
Equity-to-Asset 0.67
CPIX's Equity-to-Asset is ranked higher than
64% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. CPIX: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
CPIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.83 Max: 0.91
Current: 0.67
0.42
0.91
Debt-to-Equity 0.20
CPIX's Debt-to-Equity is ranked higher than
74% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. CPIX: 0.20 )
Ranked among companies with meaningful Debt-to-Equity only.
CPIX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: 0.49
Current: 0.2
0.02
0.49
Debt-to-EBITDA -4.18
CPIX's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. CPIX: -4.18 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CPIX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.64  Med: 0.65 Max: 3.51
Current: -4.18
-8.64
3.51
Piotroski F-Score: 3
Altman Z-Score: 2.99
Beneish M-Score: -2.87
WACC vs ROIC
5.20%
-40.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -14.65
CPIX's Operating Margin % is ranked lower than
77% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. CPIX: -14.65 )
Ranked among companies with meaningful Operating Margin % only.
CPIX' s Operating Margin % Range Over the Past 10 Years
Min: -14.65  Med: 11.58 Max: 21.06
Current: -14.65
-14.65
21.06
Net Margin % -22.65
CPIX's Net Margin % is ranked lower than
78% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. CPIX: -22.65 )
Ranked among companies with meaningful Net Margin % only.
CPIX' s Net Margin % Range Over the Past 10 Years
Min: -22.65  Med: 5.97 Max: 13.59
Current: -22.65
-22.65
13.59
ROE % -13.79
CPIX's ROE % is ranked lower than
74% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. CPIX: -13.79 )
Ranked among companies with meaningful ROE % only.
CPIX' s ROE % Range Over the Past 10 Years
Min: -13.79  Med: 3.16 Max: 27.79
Current: -13.79
-13.79
27.79
ROA % -10.00
CPIX's ROA % is ranked lower than
74% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. CPIX: -10.00 )
Ranked among companies with meaningful ROA % only.
CPIX' s ROA % Range Over the Past 10 Years
Min: -10  Med: 2.58 Max: 15.88
Current: -10
-10
15.88
ROC (Joel Greenblatt) % -548.12
CPIX's ROC (Joel Greenblatt) % is ranked lower than
84% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. CPIX: -548.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -548.12  Med: 80.07 Max: 1687
Current: -548.12
-548.12
1687
3-Year Revenue Growth Rate 7.80
CPIX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. CPIX: 7.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.4  Med: 5.3 Max: 47.3
Current: 7.8
-7.4
47.3
GuruFocus has detected 2 Warning Signs with Cumberland Pharmaceuticals Inc CPIX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CPIX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CPIX Guru Trades in Q2 2017

Jim Simons 290,853 sh (+7.63%)
John Rogers 976,377 sh (-29.91%)
» More
Q3 2017

CPIX Guru Trades in Q3 2017

Jim Simons 316,005 sh (+8.65%)
John Rogers 887,144 sh (-9.14%)
» More
Q4 2017

CPIX Guru Trades in Q4 2017

Jim Simons 330,300 sh (+4.52%)
John Rogers 910,076 sh (+2.58%)
» More
Q1 2018

CPIX Guru Trades in Q1 2018

John Rogers 1,013,926 sh (+11.41%)
Jim Simons 353,500 sh (+7.02%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2018-03-31 Add 11.41%0.01%$6.62 - $7.12 $ 6.19-10%1,013,926
John Rogers 2017-12-31 Add 2.58%$6.79 - $7.96 $ 6.19-16%910,076
John Rogers 2017-09-30 Reduce -9.14%0.01%$6.47 - $7.21 $ 6.19-10%887,144
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSXV:HVT, NSE:RPGLIFE, XKRX:018680, NAS:VERU, ROCO:6553, XKRX:012790, NAS:AGRX, TSE:4524, TPE:4144, XPAE:BPC, TSXV:GENE, BOM:524558, BSP:BIOM3, HKSE:08049, OSTO:IRLAB A, NAS:ARLZ, XCNQ:TGIF, XKRX:142280, TSXV:RX, ROCO:6472 » details
Traded in other countries:CBJ.Germany,
Headquarter Location:USA
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol.

Ratios

vs
industry
vs
history
PB Ratio 1.58
CPIX's PB Ratio is ranked higher than
74% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. CPIX: 1.58 )
Ranked among companies with meaningful PB Ratio only.
CPIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.38 Max: 4.83
Current: 1.58
0.9
4.83
PS Ratio 2.44
CPIX's PS Ratio is ranked higher than
53% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. CPIX: 2.44 )
Ranked among companies with meaningful PS Ratio only.
CPIX' s PS Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.69 Max: 6.81
Current: 2.44
1.65
6.81
EV-to-EBIT -10.49
CPIX's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. CPIX: -10.49 )
Ranked among companies with meaningful EV-to-EBIT only.
CPIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -377.8  Med: 7.1 Max: 993.7
Current: -10.49
-377.8
993.7
EV-to-EBITDA -20.27
CPIX's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. CPIX: -20.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.2  Med: 7.8 Max: 62.6
Current: -20.27
-174.2
62.6
EV-to-Revenue 1.45
CPIX's EV-to-Revenue is ranked higher than
74% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. CPIX: 1.45 )
Ranked among companies with meaningful EV-to-Revenue only.
CPIX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 1.3 Max: 6.2
Current: 1.45
0.2
6.2
Shiller PE Ratio 106.51
CPIX's Shiller PE Ratio is ranked lower than
80% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.11 vs. CPIX: 106.51 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.7  Med: 39.6 Max: 115.67
Current: 106.51
21.7
115.67
Current Ratio 4.10
CPIX's Current Ratio is ranked higher than
69% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. CPIX: 4.10 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.7 Max: 14.46
Current: 4.1
1.45
14.46
Quick Ratio 3.69
CPIX's Quick Ratio is ranked higher than
72% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. CPIX: 3.69 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.27 Max: 13.46
Current: 3.69
1.38
13.46
Days Inventory 295.79
CPIX's Days Inventory is ranked lower than
92% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. CPIX: 295.79 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 162.49  Med: 381.63 Max: 636.33
Current: 295.79
162.49
636.33
Days Sales Outstanding 57.35
CPIX's Days Sales Outstanding is ranked higher than
57% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. CPIX: 57.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.56  Med: 51.71 Max: 81.01
Current: 57.35
32.56
81.01
Days Payable 413.65
CPIX's Days Payable is ranked higher than
97% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. CPIX: 413.65 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 496.99
Current: 413.65
103.04
496.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.80
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. CPIX: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 2.45 Max: 5.1
Current: 2.8
-7
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.69
CPIX's Price-to-Net-Cash is ranked higher than
82% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.33 vs. CPIX: 4.69 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.35 Max: 6.72
Current: 4.69
1.37
6.72
Price-to-Net-Current-Asset-Value 2.65
CPIX's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.09 vs. CPIX: 2.65 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.74 Max: 5.38
Current: 2.65
1.07
5.38
Price-to-Tangible-Book 2.42
CPIX's Price-to-Tangible-Book is ranked higher than
67% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. CPIX: 2.42 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04  Med: 1.68 Max: 5.21
Current: 2.42
1.04
5.21
Price-to-Intrinsic-Value-Projected-FCF 2.13
CPIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. CPIX: 2.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.11 Max: 2.3
Current: 2.13
0.7
2.3
Price-to-Median-PS-Value 0.91
CPIX's Price-to-Median-PS-Value is ranked higher than
54% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. CPIX: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.01 Max: 2.41
Current: 0.91
0.63
2.41
Earnings Yield (Greenblatt) % -9.53
CPIX's Earnings Yield (Greenblatt) % is ranked lower than
81% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. CPIX: -9.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.2  Med: 4.2 Max: 79.2
Current: -9.53
-18.2
79.2
Forward Rate of Return (Yacktman) % -0.43
CPIX's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. CPIX: -0.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.43  Med: 3.9 Max: 18.9
Current: -0.43
-0.43
18.9

More Statistics

Revenue (TTM) (Mil) $40.10
EPS (TTM) $ -0.57
Beta0.43
Volatility12.95%
52-Week Range $5.53 - 7.96
Shares Outstanding (Mil)15.71

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}